Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide

  • Authors:
    • Iris Maria Forte
    • Paola Indovina
    • Carmelina Antonella Iannuzzi
    • Donatella Cirillo
    • Domenico Di Marzo
    • Daniela Barone
    • Francesca Capone
    • Francesca Pentimalli
    • Antonio Giordano
  • View Affiliations

  • Published online on: April 16, 2019     https://doi.org/10.3892/ijo.2019.4788
  • Pages: 2189-2199
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Glioblastoma (GB) is the most common and aggressive malignant tumor of the central nervous system. Despite current intensive treatment regimens, consisting of surgical resection followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ) chemotherapy, the prognosis of patients with GB remains extremely poor. Considering that alterations of the p53 tumor suppressor pathway have a key role in both GB development and resistance to TMZ treatment, the re‑activation of p53 could be an effective therapeutic approach against GB. In this study, we challenged p53 wild‑type and mutant GB cell lines with RITA, a molecule originally identified for its ability to restore p53 functions, although it was subsequently shown to act also through p53‑independent mechanisms. We examined the effects of RITA on GB cell viability, through MTS and clonogenic assays, and analyzed cell death through cytoflourimetric analyses. In all the tested GB cell lines, RITA significantly reduced the cell proliferative and clonogenic potential and induced cell accumulation in the S and/or G2/M cell cycle phases and massive p53‑dependent apoptosis. Moreover, RITA was more effective than the well‑known p53 re‑activating molecule, nutlin‑3, and did not affect the viability of normal astrocytes. In addition, RITA decreased survivin expression and induced DNA damage, two mechanisms that likely contribute to its anti‑tumor effects. Furthermore, RITA synergized with TMZ and was able to decrease the expression of MGMT, which is a crucial player in TMZ resistance. Thus, although further studies are warranted to clarify the exact mechanisms of action of RITA, the data of this study suggest the potential of such an approach for GB therapy, which may also help to overcome resistance to TMZ.

References

1 

Omuro A and DeAngelis LM: Glioblastoma and other malignant gliomas: A clinical review. JAMA. 310:1842–1850. 2013. View Article : Google Scholar : PubMed/NCBI

2 

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI

3 

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI

4 

Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, et al Trial Investigators: Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 376:1027–1037. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI

7 

Shajani-Yi Z, de Abreu FB, Peterson JD and Tsongalis GJ: Frequency of somatic TP53 mutations in combination with known pathogenic mutations in colon adenocarcinoma, non-small cell lung carcinoma, and gliomas as identified by mext-generation sequencing. Neoplasia. 20:256–262. 2018. View Article : Google Scholar : PubMed/NCBI

8 

Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, et al: Genetic pathways to glioblastoma: A population-based study. Cancer Res. 64:6892–6899. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Kleihues P, Schäuble B, zur Hausen A, Estève J and Ohgaki H: Tumors associated with p53 germline mutations: A synopsis of 91 families. Am J Pathol. 150:1–13. 1997.PubMed/NCBI

10 

Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, McKeever PE, Lee EY and Zhu Y: Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell. 15:514–526. 2009. View Article : Google Scholar : PubMed/NCBI

11 

Chow LM, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW and Baker SJ: Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astro-cytoma in adult brain. Cancer Cell. 19:305–316. 2011. View Article : Google Scholar : PubMed/NCBI

12 

England B, Huang T and Karsy M: Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol. 34:2063–2074. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Kang YJ, Balter B, Csizmadia E, Haas B, Sharma H, Bronson R and Yan CT: Contribution of classical end-joining to PTEN inactivation in p53-mediated glioblastoma formation and drug-resistant survival. Nat Commun. 8:140132017. View Article : Google Scholar : PubMed/NCBI

14 

Srivenugopal KS, Shou J, Mullapudi SR, Lang FF Jr, Rao JS and Ali-Osman F: Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin Cancer Res. 7:1398–1409. 2001.PubMed/NCBI

15 

Sato A, Sunayama J, Matsuda K, Seino S, Suzuki K, Watanabe E, Tachibana K, Tomiyama A, Kayama T and Kitanaka C: MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem Cells. 29:1942–1951. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Messaoudi K, Clavreul A and Lagarce F: Toward an effective strategy in glioblastoma treatment Part I: Resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug Discov Today. 20:899–905. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Wang X, Chen JX, Liu JP, You C, Liu YH and Mao Q: Gain of function of mutant TP53 in glioblastoma: Prognosis and response to temozolomide. Ann Surg Oncol. 21:1337–1344. 2014. View Article : Google Scholar

18 

Ham SW, Jeon HY, Jin X, Kim EJ, Kim JK, Shin YJ, Lee Y, Kim SH, Lee SY, Seo S, et al: TP53 gain-of-function mutation promotes inflammation in glioblastoma. Cell Death Differ. May 21–2018.Epub ahead of print. View Article : Google Scholar

19 

Pentimalli F: Updates from the TP53 universe. Cell Death Differ. 25:10–12. 2018. View Article : Google Scholar

20 

Stegh AH: Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils. Expert Opin Ther Targets. 16:67–83. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Pflaum J, Schlosser S and Müller M: p53 Family and cellular stress responses in cancer. Front Oncol. 4:2852014. View Article : Google Scholar : PubMed/NCBI

22 

Merkel O, Taylor N, Prutsch N, Staber PB, Moriggl R, Turner SD and Kenner L: When the guardian sleeps: Reactivation of the p53 pathway in cancer. Mutat Res. 773:1–13. 2017. View Article : Google Scholar : PubMed/NCBI

23 

Kim SS, Rait A, Kim E, Pirollo KF, Nishida M, Farkas N, Dagata JA and Chang EH: A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glio-blastoma to chemotherapy and improves survival. ACS Nano. 8:5494–5514. 2014. View Article : Google Scholar : PubMed/NCBI

24 

Kim SS, Rait A, Kim E, Pirollo KF and Chang EH: A tumor-targeting p53 nanodelivery system limits chemore-sistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine (Lond). 11:301–311. 2015. View Article : Google Scholar

25 

Wischhusen J, Naumann U, Ohgaki H, Rastinejad F and Weller M: CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene. 22:8233–8245. 2003. View Article : Google Scholar : PubMed/NCBI

26 

Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B and Weller M: A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 15:718–729. 2008. View Article : Google Scholar : PubMed/NCBI

27 

Villalonga-Planells R, Coll-Mulet L, Martínez-Soler F, Castaño E, Acebes JJ, Giménez-Bonafé P, Gil J and Tortosa A: Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One. 6:e185882011. View Article : Google Scholar : PubMed/NCBI

28 

Costa B, Bendinelli S, Gabelloni P, Da Pozzo E, Daniele S, Scatena F, Vanacore R, Campiglia P, Bertamino A, Gomez-Monterrey I, et al: Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. PLoS One. 8:e722812013. View Article : Google Scholar : PubMed/NCBI

29 

Daniele S, Taliani S, Da Pozzo E, Giacomelli C, Costa B, Trincavelli ML, Rossi L, La Pietra V, Barresi E, Carotenuto A, et al: Apoptosis therapy in cancer: The first single-molecule co-activating p53 and the translocator protein in glioblastoma. Sci Rep. 4:47492014. View Article : Google Scholar : PubMed/NCBI

30 

Chen X, Tai L, Gao J, Qian J, Zhang M, Li B, Xie C, Lu L and Lu W and Lu W: A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation. J Control Release. 218:29–35. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Daniele S, Barresi E, Zappelli E, Marinelli L, Novellino E, Da Settimo F, Taliani S, Trincavelli ML and Martini C: Long lasting MDM2/Translocator protein modulator: A new strategy for irreversible apoptosis of human glioblastoma cells. Oncotarget. 7:7866–7884. 2016. View Article : Google Scholar : PubMed/NCBI

32 

Daniele S, Costa B, Zappelli E, Da Pozzo E, Sestito S, Nesi G, Campiglia P, Marinelli L, Novellino E, Rapposelli S, et al: Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. Sci Rep. 5:99562015. View Article : Google Scholar : PubMed/NCBI

33 

Daniele S, La Pietra V, Barresi E, Di Maro S, Da Pozzo E, Robello M, La Motta C, Cosconati S, Taliani S, Marinelli L, et al: Lead optimization of 2-phenylindolylglyoxylyldipeptide murine double minute (MDM)2/translocator protein (TSPO) dual inhibitors for the treatment of gliomas. J Med Chem. 59:4526–4538. 2016. View Article : Google Scholar : PubMed/NCBI

34 

Patyka M, Sharifi Z, Petrecca K, Mansure J, Jean-Claude B and Sabri S: Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status. Oncotarget. 7:60245–60269. 2016. View Article : Google Scholar : PubMed/NCBI

35 

Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C, Guehennec J, Knoff D, Labussière M, Marie Y, et al: Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2-amplified and TP53 wild-type glio-blastomas. Clin Cancer Res. 22:1185–1196. 2016. View Article : Google Scholar

36 

Renner G, Janouskova H, Noulet F, Koenig V, Guerin E, Bär S, Nuesch J, Rechenmacher F, Neubauer S, Kessler H, et al: Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma. Cell Death Differ. 23:640–653. 2016. View Article : Google Scholar

37 

Wang H, Cai S, Bailey BJ, Reza Saadatzadeh M, Ding J, Tonsing-Carter E, Georgiadis TM, Zachary Gunter T, Long EC, Minto RE, et al: Combination therapy in a xenograft model of glio-blastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist. J Neurosurg. 126:446–459. 2017. View Article : Google Scholar

38 

Mai WX, Gosa L, Daniels VW, Ta L, Tsang JE, Higgins B, Gilmore WB, Bayley NA, Harati MD, Lee JT, et al: Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nat Med. 23:1342–1351. 2017. View Article : Google Scholar : PubMed/NCBI

39 

Merlino F, Daniele S, La Pietra V, Di Maro S, Di Leva FS, Brancaccio D, Tomassi S, Giuntini S, Cerofolini L, Fragai M, et al: Simultaneous targeting of RGD-integrins and dual murine double minute proteins in glioblastoma multiforme. J Med Chem. 61:4791–4809. 2018. View Article : Google Scholar : PubMed/NCBI

40 

Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A and Selivanova G: Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med. 10:1321–1328. 2004. View Article : Google Scholar : PubMed/NCBI

41 

Dickinson ER, Jurneczko E, Nicholson J, Hupp TR, Zawacka-Pankau J, Selivanova G and Barran PE: The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors. Front Mol Biosci. 2:392015. View Article : Google Scholar : PubMed/NCBI

42 

Krajewski M, Ozdowy P, D’Silva L, Rothweiler U and Holak TA: NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med. 11:1135–1136; author reply 1136–1137. 2005. View Article : Google Scholar : PubMed/NCBI

43 

Du Z, Yu J, Li F, Deng L, Wu F, Huang X, Bergstrand J, Widengren J, Dong C and Ren J: In situ monitoring of p53 protein and MDM2 protein interaction in single living cells using single-molecule fluorescence spectroscopy. Anal Chem. 90:6144–6151. 2018. View Article : Google Scholar : PubMed/NCBI

44 

Di Conza G, Buttarelli M, Monti O, Pellegrino M, Mancini F, Pontecorvi A, Scotlandi K and Moretti F: IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells. Mol Cancer Ther. 11:1247–1256. 2012. View Article : Google Scholar : PubMed/NCBI

45 

Henze J, Mühlenberg T, Simon S, Grabellus F, Rubin B, Taeger G, Schuler M, Treckmann J, Debiec-Rychter M, Taguchi T, et al: p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One. 7:e377762012. View Article : Google Scholar : PubMed/NCBI

46 

Chuang HC, Yang LP, Fitzgerald AL, Osman A, Woo SH, Myers JN and Skinner HD: The p53-reactivating small molecule RITA induces senescence in head and neck cancer cells. PLoS One. 9:e1048212014. View Article : Google Scholar : PubMed/NCBI

47 

Surget S, Descamps G, Brosseau C, Normant V, Maïga S, Gomez-Bougie P, Gouy-Colin N, Godon C, Béné MC, Moreau P, et al: RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway. BMC Cancer. 14:4372014. View Article : Google Scholar

48 

Weilbacher A, Gutekunst M, Oren M, Aulitzky WE and van der Kuip H: RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death Dis. 5:e13182014. View Article : Google Scholar : PubMed/NCBI

49 

Wanzel M, Vischedyk JB, Gittler MP, Gremke N, Seiz JR, Hefter M, Noack M, Savai R, Mernberger M, Charles JP, et al: CRISPR-Cas9-based target validation for p53-reactivating model compounds. Nat Chem Biol. 12:22–28. 2016. View Article : Google Scholar :

50 

Hedström E, Eriksson S, Zawacka-Pankau J, Arnér ES and Selivanova G: p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Cell Cycle. 8:3584–3591. 2009. View Article : Google Scholar : PubMed/NCBI

51 

Shi Y, Nikulenkov F, Zawacka-Pankau J, Li H, Gabdoulline R, Xu J, Eriksson S, Hedström E, Issaeva N, Kel A, et al: ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ. 21:612–623. 2014. View Article : Google Scholar : PubMed/NCBI

52 

Saha MN, Jiang H, Yang Y, Zhu X, Wang X, Schimmer AD, Qiu L and Chang H: Targeting p53 via JNK pathway: A novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One. 7:e302152012. View Article : Google Scholar : PubMed/NCBI

53 

Nieves-Neira W, Rivera MI, Kohlhagen G, Hursey ML, Pourquier P, Sausville EA and Pommier Y: DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Mol Pharmacol. 56:478–484. 1999. View Article : Google Scholar : PubMed/NCBI

54 

Yang J, Ahmed A, Poon E, Perusinghe N, de Haven Brandon A, Box G, Valenti M, Eccles S, Rouschop K, Wouters B, et al: Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol. 29:2243–2253. 2009. View Article : Google Scholar : PubMed/NCBI

55 

Ahmed A, Yang J, Maya-Mendoza A, Jackson DA and Ashcroft M: Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1. Cell Death Dis. 2:e1602011. View Article : Google Scholar : PubMed/NCBI

56 

de Lange J, Verlaan-de Vries M, Teunisse AF and Jochemsen AG: Chk2 mediates RITA-induced apoptosis. Cell Death Differ. 19:980–989. 2012. View Article : Google Scholar :

57 

Wiegering A, Matthes N, Mühling B, Koospal M, Quenzer A, Peter S, Germer CT, Linnebacher M and Otto C: Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin. Neoplasia. 19:301–309. 2017. View Article : Google Scholar : PubMed/NCBI

58 

Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, Gluch A, Kel A, Sangfelt O and Selivanova G: Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell. 15:441–453. 2009. View Article : Google Scholar : PubMed/NCBI

59 

Enge M, Bao W, Hedström E, Jackson SP, Moumen A and Selivanova G: MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell. 15:171–183. 2009. View Article : Google Scholar : PubMed/NCBI

60 

Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, et al: Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle. 13:652–665. 2014. View Article : Google Scholar

61 

Saha MN, Jiang H, Mukai A and Chang H: RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses. Mol Cancer Ther. 9:3041–3051. 2010. View Article : Google Scholar : PubMed/NCBI

62 

Shin D, Kim EH, Lee J and Roh JL: RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems. Redox Biol. 13:219–227. 2017. View Article : Google Scholar : PubMed/NCBI

63 

Zhao CY, Grinkevich VV, Nikulenkov F, Bao W and Selivanova G: Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle. 9:1847–1855. 2010. View Article : Google Scholar : PubMed/NCBI

64 

Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ and Orlowski RZ: Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther. 11:2243–2253. 2012. View Article : Google Scholar : PubMed/NCBI

65 

Burmakin M, Shi Y, Hedström E, Kogner P and Selivanova G: Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res. 19:5092–5103. 2013. View Article : Google Scholar : PubMed/NCBI

66 

Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S and Donadelli M: Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochim Biophys Acta. 1853:89–100. 2015. View Article : Google Scholar

67 

Menendez D, Lowe JM, Snipe J and Resnick MA: Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells. Oncotarget. 7:61630–61642. 2016. View Article : Google Scholar : PubMed/NCBI

68 

He XY, Feng XL, Song XP, Zeng HC, Cao ZX, Xiao WW, Zhang B and Wu QH: RITA combined with temozolomide inhibits the proliferation of human glioblastoma U87 cells. Nan Fang Yi Ke Da Xue Xue Bao. 36:1423–1428. 2016.In Chinese. PubMed/NCBI

69 

Bacciocchi G, Gibelli N, Zibera C, Pedrazzoli P, Bergamaschi G, De Piceis Polver P, Danova M, Mazzini G, Palomba L, Tupler R, et al: Establishment and characterization of two cell lines derived from human glioblastoma multiforme. Anticancer Res. 12:853–861. 1992.PubMed/NCBI

70 

Wang X, Chen JX, Liu YH, You C and Mao Q: Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase. Neurol Sci. 34:1421–1428. 2013. View Article : Google Scholar

71 

Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV and Gudkov AV: A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 285:1733–1737. 1999. View Article : Google Scholar : PubMed/NCBI

72 

Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, et al: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 21:2613–2622. 2002. View Article : Google Scholar : PubMed/NCBI

73 

Hoffman WH, Biade S, Zilfou JT, Chen J and Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 277:3247–3257. 2002. View Article : Google Scholar

74 

Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y, Kobune M, Miyagishi M, Taira K, Tahara H, et al: Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther. 10:162–171. 2004. View Article : Google Scholar : PubMed/NCBI

75 

Saito T, Sugiyama K, Takeshima Y, Amatya VJ, Yamasaki F, Takayasu T, Nosaka R, Muragaki Y, Kawamata T and Kurisu K: Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurosurg. 128:679–684. 2018. View Article : Google Scholar

76 

Faccion RS, Bernardo PS, de Lopes GPF, Bastos LS, Teixeira CL, de Oliveira JA, Fernandes PV, Dubois LG, Chimelli L and Maia RC: p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors. Cell Oncol (Dordr). 41:141–157. 2018. View Article : Google Scholar

77 

Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q and Loeffler J: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene. 23:7494–7506. 2004. View Article : Google Scholar : PubMed/NCBI

78 

Guvenc H, Pavlyukov MS, Joshi K, Kurt H, Banasavadi-Siddegowda YK, Mao P, Hong C, Yamada R, Kwon CH, Bhasin D, et al: Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res. 19:631–642. 2013. View Article : Google Scholar

79 

Dahan P, Martinez Gala J, Delmas C, Monferran S, Malric L, Zentkowski D, Lubrano V, Toulas C, Cohen-Jonathan Moyal E and Lemarie A: Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: Possible involvement in radioresistance. Cell Death Dis. 5:e15432014. View Article : Google Scholar : PubMed/NCBI

80 

Fenstermaker RA, Figel SA, Qiu J, Barone TA, Dharma SS, Winograd EK, Galbo PM, Wiltsie LM and Ciesielski MJ: Survivin monoclonal antibodies detect survivin cell surface expression and inhibit tumor growth in vivo. Clin Cancer Res. 24:2642–2652. 2018. View Article : Google Scholar : PubMed/NCBI

81 

Lee SY: Temozolomide resistance in glioblastoma multiforme. Genes Dis. 3:198–210. 2016. View Article : Google Scholar : PubMed/NCBI

82 

Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI

83 

Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B and Weller M: O6-methylguanine DNA meth-yltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 96:766–776. 2006. View Article : Google Scholar : PubMed/NCBI

84 

Gottlieb A, Althoff K, Grunewald L, Thor T, Odersky A, Schulte M, Deubzer HE, Heukamp L, Eggert A, Schramm A, et al: RITA displays anti-tumor activity in medulloblastomas independent of TP53 status. Oncotarget. 8:27882–27891. 2017. View Article : Google Scholar : PubMed/NCBI

85 

Ziegler DS, Kung AL and Kieran MW: Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol. 26:493–500. 2008. View Article : Google Scholar : PubMed/NCBI

86 

Sohn D, Graupner V, Neise D, Essmann F, Schulze-Osthoff K and Jänicke RU: Pifithrin-alpha protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53. Cell Death Differ. 16:869–878. 2009. View Article : Google Scholar : PubMed/NCBI

87 

Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD and Sarkaria JN: Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-oncol. 11:281–291. 2009. View Article : Google Scholar :

Related Articles

Journal Cover

June 2019
Volume 54 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Forte, I.M., Indovina, P., Iannuzzi, C.A., Cirillo, D., Di Marzo, D., Barone, D. ... Giordano, A. (2019). Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. International Journal of Oncology, 54, 2189-2199. https://doi.org/10.3892/ijo.2019.4788
MLA
Forte, I. M., Indovina, P., Iannuzzi, C. A., Cirillo, D., Di Marzo, D., Barone, D., Capone, F., Pentimalli, F., Giordano, A."Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide". International Journal of Oncology 54.6 (2019): 2189-2199.
Chicago
Forte, I. M., Indovina, P., Iannuzzi, C. A., Cirillo, D., Di Marzo, D., Barone, D., Capone, F., Pentimalli, F., Giordano, A."Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide". International Journal of Oncology 54, no. 6 (2019): 2189-2199. https://doi.org/10.3892/ijo.2019.4788